May 2 |
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
|
Apr 30 |
Invivyd cuts 14 positions, expects to end 2024 with at least $75M in cash
|
Apr 30 |
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
|
Apr 15 |
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
|
Apr 12 |
Invivyd appoints Jeremy Gowler as interim CEO
|
Apr 12 |
Invivyd Announces CEO Transition
|
Apr 7 |
We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate
|
Apr 4 |
Invivyd provides Pemgarda 2024 net product revenue guidance
|
Apr 4 |
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
|
Mar 28 |
Invivyd GAAP EPS of -$1.81
|